Related Experiment Video
Updated: Apr 22, 2026

07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
8.9K
[Intensive therapy for patients with Guillian-Barré syndrome]
1Risengård 9, 8700 Horsens. lonebuus@mail.tele.dk.
Ugeskrift for Laeger
|October 16, 2014
Summary
Guillain-Barré syndrome can cause respiratory failure, necessitating mechanical ventilation. This review explores optimal timing for respiratory support and associated complications in Guillain-Barré syndrome patients.
Area of Science:
- Neurology
- Critical Care Medicine
Background:
- Guillain-Barré syndrome is a primary cause of acute flaccid paralysis globally.
- A significant portion of patients (approximately 25%) experience respiratory failure, requiring intensive care and mechanical ventilation.
Purpose of the Study:
- To determine the optimal timing for initiating respiratory supportive therapy in Guillain-Barré syndrome.
- To review and discuss the various complications associated with Guillain-Barré syndrome.
Main Methods:
- Literature review focusing on respiratory management and complications in Guillain-Barré syndrome.
- Analysis of studies addressing the timing of mechanical ventilation and intensive care interventions.
Main Results:
- Respiratory failure is a critical complication in Guillain-Barré syndrome, often requiring mechanical ventilation.
- Early recognition and intervention for respiratory compromise are crucial for patient outcomes.
Conclusions:
- Optimal timing for respiratory support initiation is key to managing Guillain-Barré syndrome.
- Understanding and managing complications are vital for improving patient prognosis in Guillain-Barré syndrome.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Myasthenia Gravis: Diagnostic Tests
3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Depolarizing Blockers: Pharmocokinetics
766
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
766
Acute Coronary Syndrome IV: Interprofessional Care
512
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
512
Myasthenia Gravis ll: Pathophysiology
18
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
18

